
Dennis A. Priebat MD
Associate Professor of Medicine, Geo Wash University
Join to view full profile
110 Irving St NwSuite 2a38Washington, DC 20010
Phone+1 202-877-2505
Fax+1 202-877-8910
Dr. Priebat is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 1978 - 1982
MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 1975 - 1977
Stony Brook University Health Sciences Center School of MedicineClass of 1975
Certifications & Licensure
DC State Medical License 1977 - 2027
CA State Medical License 1982 - 2025
MD State Medical License 1977 - 2017
UT State Medical License 1980 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013, 2015-2017
- CMS Meaningful Use Stage 2 Certification MEDSEEK Empower, SymphonyCare, LLC, 2013, 2015-2017
Clinical Trials
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 08
Publications & Presentations
PubMed
- 155 citationsCorrelative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumabEmily Z. Keung, Melissa Amber Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales
Clinical Cancer Research. 2020-03-15 - 23 citationsAssociation of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.Scott M. Schuetze, Vanessa Bolejack, Dafydd G. Thomas, Margaret von Mehren, Shreyaskumar Patel
JAMA Oncology. 2018-06-01 - 72 citationsResults of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcomaBrian L. Samuels, Sant P. Chawla, Neeta Somaiah, Arthur P. Staddon, Keith M. Skubitz
Cancer. 2017-12-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









